iShares Biotechnology ETF (IBB) was flat in early 2026 despite broader market declines and volatility. High buyout-premium M&A, led by Biogen's $5.6B acquisition of Apellis, has underpinned sector outperformance and produced an uptick in investor enthusiasm.
iShares Biotechnology ETF (IBB) was flat in early 2026 despite broader market declines and volatility. High buyout-premium M&A, led by Biogen's $5.6B acquisition of Apellis, has underpinned sector outperformance and produced an uptick in investor enthusiasm.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
